Defining Oligometastatic Bladder Cancer: A Systematic Review

International Agency for Research on Cancer, 2019 Bamias, 2019, The impact of cisplatin- or non-cisplatin-containing chemotherapy on long-term and conditional survival of patients with advanced urinary tract cancer, Oncologist, 24, 1348, 10.1634/theoncologist.2018-0739 Pierantoni, 2019, Immunotherapy and urothelial carcinoma: an overview and future prospectives, Crit Rev Oncol Haematol, 143, 46, 10.1016/j.critrevonc.2019.08.005 Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Reyes, 2015, The biology and treatment of oligometastatic cancer, Oncotarget, 6, 8491, 10.18632/oncotarget.3455 Planchard, 2018, Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv192, 10.1093/annonc/mdy275 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Harrow, 2022, Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes, Int J Radiat Oncol Biol Phys, 114, 611, 10.1016/j.ijrobp.2022.05.004 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Horwich, 2019, EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees, Ann Oncol, 30, 1697, 10.1093/annonc/mdz296 Ogihara, 2017, Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy?, Oncotarget, 8, 111819, 10.18632/oncotarget.22911 Patel, 2017, Survival after metastasectomy for metastatic urothelial carcinoma: a systematic review and meta-analysis, Bladder Cancer, 3, 121, 10.3233/BLC-170108 Abufaraj, 2018, The role of surgery in metastatic bladder cancer: a systematic review, Eur Urol, 73, 543, 10.1016/j.eururo.2017.09.030 Galsky, 2016, Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement, J Clin Oncol, 34, 2627, 10.1200/JCO.2016.67.5033 Flaig, 2020, Bladder cancer, version 3.2020, J Natl Compr Cancer Netw, 18, 329, 10.6004/jnccn.2020.0011 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, J Clin Epidemiol, 62, e1, 10.1016/j.jclinepi.2009.06.006 Franzese, 2021, Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies, Clin Oncol, 33, 50, 10.1016/j.clon.2020.07.008 Muilwijk, 2020, Metastasectomy of oligometastatic urothelial cancer: a single-center experience, Transl Androl Urol, 9, 1296, 10.21037/tau-19-624 Berghen, 2020, Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news, eCancer, 14, 1036, 10.3332/ecancer.2020.1036 Francolini, 2019, Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience, Cancer Treat Res Commun, 19 Augugliaro, 2019, Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?, Neoplasma, 66, 160, 10.4149/neo_2018_180522N333 Leonetti, 2018, Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series, Int J Urol, 25, 879, 10.1111/iju.13773 Verghote, 2021, Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial, BMC Cancer, 21, 1113, 10.1186/s12885-021-08861-x González-del-Alba, 2022, Management of patients with metastatic bladder cancer in the real-world setting from the multidisciplinary team: current opinion of the SOGUG Multidisciplinary Working Group, Cancers, 14, 1130, 10.3390/cancers14051130 Aboudaram, 2023, Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis, Cancers, 15, 1161, 10.3390/cancers15041161 Longo, 2022, Metastasis-directed radiation therapy with consolidative intent for oligometastatic urothelial carcinoma: a systematic review and meta-analysis, Cancers, 14, 2373, 10.3390/cancers14102373 Miranda, 2021, Metastasis-directed radiation therapy after radical cystectomy for bladder cancer, Urol Oncol, 39, 790.e1, 10.1016/j.urolonc.2021.05.005 Abe, 2020, Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy, Jpn J Clin Oncol, 50, 206, 10.1093/jjco/hyz197 Stecca, 2021, Metastatic urothelial cancer: a rapidly changing treatment landscape, Ther Adv Med Oncol, 13, 10.1177/17588359211047352 Kanzaki, 2010, Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma, Int Cardiovasc Thorac Surg, 11, 60, 10.1510/icvts.2010.236687 Iwamoto, 2016, Metastasectomy improves survival in patients with metastatic urothelial carcinoma, Anticancer Res, 36, 5557, 10.21873/anticanres.11140 Manig, 2016, Predicting survival after irradiation of metastases from transitional carcinoma of the bladder, Anticancer Res, 36, 6663, 10.21873/anticanres.11275 Takashige, 2011, Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma, Ann Thorac Surg, 92, 449, 10.1016/j.athoracsur.2011.03.097 Takashige, 2014, Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan, J Urol, 191, 932, 10.1016/j.juro.2013.11.004 Bekku, 2013, Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?, Int J Clin Oncol, 18, 110, 10.1007/s10147-011-0350-z Faltas, 2018, Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes, Urol Oncol, 36, 9.e11, 10.1016/j.urolonc.2017.09.009 Dodd, 1999, Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma, J Clin Oncol, 17, 2546, 10.1200/JCO.1999.17.8.2546 Siefker-Radtke, 2004, Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience, J Urol, 171, 145, 10.1097/01.ju.0000099823.60465.e6 Lehmann, 2009, Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05), Eur Urol, 55, 1293, 10.1016/j.eururo.2008.11.039 Lievens, 2020, Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document, Radiother Oncol, 148, 157, 10.1016/j.radonc.2020.04.003 Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1 Bajorin, 2021, Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma, N Engl J Med, 384, 2102, 10.1056/NEJMoa2034442 Mertens, 2017, Related to: [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer, Scand J Urol, 51, 351, 10.1080/21681805.2017.1329229 Zattoni, 2019, 18F-FDG PET/CT and urothelial carcinoma: impact on management and prognosis—a multicenter retrospective study, Cancers, 11, 700, 10.3390/cancers11050700 Bajorin, 1999, Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J Clin Oncol, 17, 3173, 10.1200/JCO.1999.17.10.3173 Bellmunt, 2010, Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, 28, 1850, 10.1200/JCO.2009.25.4599 Sonpavde, 2016, Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma, J Urol, 195, 277, 10.1016/j.juro.2015.07.111